Monoclonal Antibodies: Usage in the Treatment of COVID-19 Infection
Santosh Kumar Rada
GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.
Hema Latha Maramreddy *
GITAM Institute of Pharmacy, GITAM (Deemed to be University), Visakhapatnam, Andhra Pradesh, India.
*Author to whom correspondence should be addressed.
Abstract
Since the COVID-19 emergence in December 2019, significant efforts are being made in the hunt for appropriate medical interventions. This forces scientists to produce or discover traditional curative medications, preventive vaccinations, or passive immunological techniques as quickly as possible. Therapeutic monoclonal antibodies (mAbs) have drawn a lot of interest throughout this context. COVID-19 approved Emergency Use Authorization (EUA) medications for the outpatient treatment of mild to moderate symptoms for many monoclonal antibodies (mAbs) aimed against the Receptor binding domain of the S protein of the coronavirus 2 (SARS-CoV-2). We investigated the feasibility of monoclonal antibodies for the diagnosis and treatment of COVID-19 infection in this review. Human monoclonal antibodies targeted SARS-CoV-2 viral protein domains, especially the spike protein area, and hyper-immune plasma from recovered COVID-19 patients are also included in this review. In summary, monoclonal antibodies are the promising remedies that could be used to regulate the SARS-CoV-2 (COVID-19 infection causal agent) through immunotherapy, vaccine development, and viral screening.
Keywords: Monoclonal antibodies, SARS-CoV-2, vaccine development, immunotherapy, COVID-19